Mesothelioma, a cancer mainly caused by asbestos exposure, is typically found in older Americans. One problem with mesothelioma is that it is hard to tell between reactive and cancerous cells. A study in the American Journal of Pathology sheds light and expands on this information. The study found a biomarker,[…]
From the blog
Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma
This is a multicenter, single-arm, phase II clinical study to evaluate the safety and efficacy of Cadonilimab combined with gemcitabine, or vinorelbine, or pemetrexed in the treatment of patients with recurrent / refractory pleural mesothelioma.
Palliative Care Improves Lives of Mesothelioma Patients
Palliative care is an essential part of the cancer treatment process. It helps improve the quality of life of people with life threatening illnesses like mesothelioma. It is important for doctors to know the range of symptoms patients experience to help provide the best care possible. Palliative care is a[…]
Delayed Care for Mesothelioma Could be Beneficial for Patients
Mesothelioma, a cancer mainly caused by asbestos, is very hard to treat. A new study wanted to see if treating mesothelioma immediately is the best option for certain patients. The study, which was published in Clinical Lung Cancer, looks at patients with inoperable pleural mesothelioma. The study compared patients who[…]
Surgery Improves Survival in Mesothelioma Patients
There is a debate about whether surgery for mesothelioma is beneficial. A new study was presented at the World Conference on Lung Cancer. The study looked at the survival of pleural mesothelioma patients who had different types of treatment. These included chemotherapy followed by surgery and chemotherapy only. The goal[…]
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
This phase I/II trial studies the side effects and the best dose of methoxyamine when given together with cisplatin and pemetrexed disodium and to see how well it works in treating patients with solid tumors or mesothelioma that have spread to other places in the body and usually cannot be cured or controlled with standard treatment (advanced), or mesothelioma that does not respond to pemetrexed disodium and cisplatin or carboplatin (refractory). Methoxyamine may shrink the tumor and may also help cisplatin and pemetrexed disodium work better by making tumor cells more sensitive to the drugs. Drugs used in chemotherapy, such as cisplatin and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving methoxyamine together with cisplatin and pemetrexed disodium may be a better treatment for solid tumors or mesothelioma than methoxyamine and pemetrexed disodium.
How the Immune System is Affected by Pleural Mesothelioma
A recent study looked at the body’s immune system and how it responds to pleural mesothelioma, a cancer of the lining of the lungs. Results were published in the journal Pathobiology. The immune cells around the tumor area of 60 pleural mesothelioma patients were studied. The researchers used biomarkers to[…]
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Primary Outcome Measures Number of participants treated with Alintegimod monotherapy with treatment related adverse events as assessed by CTCAEv5.0 Number of participants treated with Alintegimod in combination with treatment related adverse events as assessed by CTCAEv5.0 Define RPTDs for Alintegimod Secondary Outcome Measures Characterize Pharmacokinetics of Alintegimod monotherapy by measuring[…]
Mesothelioma’s Effects on Mental Health
Mesothelioma is a tough cancer to live with that is incurable and caused by asbestos. A recent study published in the European Journal of Oncology Nursing looked at the impact of mesothelioma on mental health and wellbeing. The frequency of mental health conditions among patients and caregivers was also examined.[…]
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens.
Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b
